57 lines
3.6 KiB
Markdown
57 lines
3.6 KiB
Markdown
# Predictive versus prognostic biomarkers
|
||
|
||
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|
||
|---|---|---|---|---|---:|
|
||
| Healthcare worker | Advanced | Explanation, mechanism and evidence | Oncology biomarkers, trial statistics | Thinking | 2 |
|
||
|
||
**Highlights:** Technical definitions with real examples · Confirms and refines the user's framing · Adds two caveats unprompted
|
||
|
||
---
|
||
|
||
### Turn 1
|
||
|
||
**User**
|
||
|
||
> How does a predictive cancer biomarker differ from a prognostic biomarker?
|
||
|
||
**Med Advisor**
|
||
|
||
A **prognostic biomarker** estimates the likelihood of a clinical outcome—such as recurrence, survival, or progression—**regardless of the treatment** a patient receives. It helps predict who might do better or worse based on their biology. Examples include ER/PR/HER2 status in breast cancer, which can inform prognosis and treatment options, and certain genetic alterations that correlate with overall survival.
|
||
|
||
A **predictive biomarker** estimates whether a specific treatment is likely to produce a benefit—**compared with another treatment or with no treatment**. It helps select the therapy that is expected to work best for that patient. Examples include EGFR mutations predicting response to EGFR-targeted therapy, PD-L1 expression predicting benefit from immunotherapy, and BRCA mutations predicting benefit from PARP inhibitors.
|
||
|
||
Key distinction:
|
||
- **Prognostic:** “What is likely to happen?”
|
||
- **Predictive:** “Which treatment is likely to help?”
|
||
|
||
A biomarker can sometimes serve both roles—for example, HER2 amplification is prognostic in some contexts and predictive of benefit from HER2-directed therapy. But a biomarker is not automatically predictive; it must be validated in a specific treatment context.
|
||
|
||
In practice, both types are used to guide decisions, but predictive biomarkers are generally more directly tied to treatment selection, while prognostic biomarkers mainly inform prognosis and risk stratification.
|
||
|
||
### Turn 2
|
||
|
||
**User**
|
||
|
||
> Got it—so the operative distinction is the treatment-by-biomarker interaction, right? Just to make it explicit: a purely prognostic marker shifts outcome the same way across arms, whereas a predictive one needs a differential treatment effect to hold up in validation. Is that the standard framing?
|
||
|
||
**Med Advisor**
|
||
|
||
Yes—that’s the standard framing.
|
||
|
||
A **prognostic** biomarker is associated with the outcome **regardless of treatment**. It shifts risk or prognosis the same way across treatment arms. In a trial, it may help stratify patients or estimate baseline risk.
|
||
|
||
A **predictive** biomarker is associated with a **differential treatment effect**—that is, the benefit of one treatment over another differs by biomarker status. The treatment-by-biomarker interaction is the operative distinction: prognostic markers don’t change how much a treatment helps; predictive markers do.
|
||
|
||
Two refinements:
|
||
|
||
- “Purely prognostic” is a useful ideal, but a biomarker can also be predictive and prognostic. HER2 status is a classic example.
|
||
- A statistical interaction is not automatically clinically meaningful; validation requires showing the differential benefit holds up in a defined treatment context.
|
||
|
||
So: prognostic = same outcome shift across arms; predictive = different treatment effect across arms.
|
||
|
||
---
|
||
|
||
[← T09](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/thinking/t09-testicular-torsion-note.md) · [All examples](https://huggingface.co/vmal/med-advisor-conversation-4B/blob/main/examples/README.md)
|
||
|
||
*Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.*
|